Nantahala Capital Management LLC Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

Nantahala Capital Management LLC increased its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 33.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,000,000 shares of the company’s stock after purchasing an additional 250,000 shares during the period. Nantahala Capital Management LLC’s holdings in scPharmaceuticals were worth $3,540,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Legato Capital Management LLC bought a new stake in scPharmaceuticals during the 4th quarter valued at $37,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of scPharmaceuticals during the fourth quarter valued at about $38,000. Virtu Financial LLC purchased a new stake in shares of scPharmaceuticals during the third quarter valued at about $46,000. Price T Rowe Associates Inc. MD bought a new stake in shares of scPharmaceuticals in the 4th quarter valued at about $54,000. Finally, Wells Fargo & Company MN grew its position in shares of scPharmaceuticals by 110.5% in the 4th quarter. Wells Fargo & Company MN now owns 18,407 shares of the company’s stock worth $65,000 after buying an additional 9,663 shares during the last quarter. 89.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, March 20th. Maxim Group lowered their price target on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 20th.

scPharmaceuticals Price Performance

NASDAQ SCPH opened at $2.51 on Monday. The stock’s fifty day moving average price is $2.81 and its 200 day moving average price is $3.35. scPharmaceuticals Inc. has a 1 year low of $1.94 and a 1 year high of $5.65. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The company has a market cap of $126.21 million, a price-to-earnings ratio of -1.32 and a beta of 0.38.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The firm had revenue of $12.15 million during the quarter, compared to analysts’ expectations of $12.08 million. As a group, equities research analysts forecast that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.